{
    "clinical_study": {
        "@rank": "127800", 
        "acronym": "KOPIN", 
        "arm_group": [
            {
                "arm_group_label": "micafungin", 
                "arm_group_type": "Experimental", 
                "description": "micafungin sodium IV (Mycamine\u00ae)"
            }, 
            {
                "arm_group_label": "Fluconazole", 
                "arm_group_type": "Active Comparator", 
                "description": "Fluconazole IV (use same brand in each hospital)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate non-inferiority of micafungin at a dose of 100\n      mg/day versus fluconzeole for the prevention of Invasive Fungal Disease, defined according\n      to the revised EORTC/MSG criteria, undergoing living-donor liver transplantation."
        }, 
        "brief_title": "Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Transplant Recipient", 
        "condition_browse": {
            "mesh_term": "Mycoses"
        }, 
        "detailed_description": {
            "textblock": "This is Randomized, Open label, Non-inferiority Study of Micafungin versus Fluconazole for\n      the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients\n\n      After transplant subjects will be randomized to one of the following treatment arms:\n\n        -  Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing <40 kg)\n\n        -  Fluconazole 100~200mg/day, IV care until oral medication becomes possible\n\n      Stratification according to centers. Antifungal prophylaxis will be administered once daily\n      for a period of 21 days, or until hospital discharge, whichever occurs first.\n\n      This is an open label study; Study center personnel will not be blinded to treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 20 years.\n\n          -  Undergoing Living Donor Liver Transplantation(LDLT)\n\n        Exclusion Criteria:\n\n          -  Any systemic antifungal therapy (excluding fluconazole or SDD for a maximum of 7\n             days) within 14 days prior to randomization.\n\n          -  Evidence of documented ('proven' or 'probable') or suspected ('possible') IFD\n             (according to the EORTC/MSG criteria).\n\n          -  Allergy, hypersensitivity, or any serious reaction to an echinocandin antifungal, or\n             any of the study drugs or their excipients.\n\n          -  Reimplantation or orthotopic transplantation patient."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "172", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974375", 
            "org_study_id": "MYC-LT-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "micafungin", 
                "description": "Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing <40 kg)", 
                "intervention_name": "micafungin", 
                "intervention_type": "Drug", 
                "other_name": "Mycamine"
            }, 
            {
                "arm_group_label": "Fluconazole", 
                "description": "Fluconazole 100~200mg/day, IV care until oral medication becomes possible", 
                "intervention_name": "Fluconazole", 
                "intervention_type": "Drug", 
                "other_name": "Fluconazole"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluconazole", 
                "Micafungin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Living donor", 
            "Liver transplant", 
            "antifungal prevention"
        ], 
        "lastchanged_date": "October 27, 2013", 
        "location": {
            "contact": {
                "email": "drsong71@hotmail.com", 
                "last_name": "Giwon Song, Professor", 
                "phone": "+82-10-8794-8701"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open Label, Non-inferiority Study of Micafungin Versus Fluconazole for the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients", 
        "overall_contact": {
            "email": "drsong71@hotmail.com", 
            "last_name": "Giwon Song, Professor", 
            "phone": "+82-10-8794-8701"
        }, 
        "overall_official": [
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "SUNG-GYU LEE, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Giwon Song, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University", 
                "last_name": "Namjoon Lee, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Samsung Medical Center", 
                "last_name": "Jaewon Joh, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Daegu Catholic University Medical Center", 
                "last_name": "Dong-Lak Choi, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Severance Hospital", 
                "last_name": "Myung Soo Kim, professor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To demonstrate non-inferiority of micafungin at a dose of 100 mg/day versus fluconzeole for the prevention of Invasive Fungal Disease, defined according to the revised EORTC/MSG criteria, undergoing living-donor liver transplantation.\n'Clinical success' at the End of Prophylaxis as assessed by the investigator.\nAbsence of a 'proven' or 'probable' IFD AND No initiation of antifungal treatment (additional antifungal medication or increase in the dose of the study drug due to lack of efficacy)", 
            "measure": "Prevention of invasive fungal disease", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974375"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Giwon Song", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "no events of proven/probable IFD at end of prophylaxis visit and end of study visit", 
                "measure": "no events of proven/probable IFD", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Time to proven/probable IFD", 
                "measure": "ime to proven/probable IFD", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "fungal-free survival et end of study/and long-term follow-up visit", 
                "measure": "fungal-free survival", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "incidence of superficial mycosis infection and colonization at the end of prophylaxis compare to baseline", 
                "measure": "incidence of superficial mycosis infection and colonization", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "saftey by variables of viatl sign/physical examination/laboratory test", 
                "measure": "saftey by variables", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "cases of adverse events", 
                "measure": "cases of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}